{
    "data": [
        {
            "id": "4228942",
            "type": "article",
            "attributes": {
                "publishOn": "2018-12-18T09:57:35-05:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: Blank Check On Growth?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104054",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "1837",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4228942-mylan-blank-check-on-growth"
            }
        },
        {
            "id": "4222263",
            "type": "article",
            "attributes": {
                "publishOn": "2018-11-14T16:28:00-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan's Issues Persist But Expectations Are Low And Several Catalysts Are Coming",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "78545",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "21787",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4222263-mylans-issues-persist-expectations-are-low-and-several-catalysts-are-coming"
            }
        },
        {
            "id": "4221253",
            "type": "article",
            "attributes": {
                "publishOn": "2018-11-12T08:40:40-05:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: On The Road To Recovery",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101850",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4221253-mylan-on-road-to-recovery"
            }
        },
        {
            "id": "4210856",
            "type": "article",
            "attributes": {
                "publishOn": "2018-10-10T08:50:00-04:00",
                "isLockedPro": false,
                "commentCount": 138,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Greenlight Capital's (David Einhorn) Q3 2018 Letter",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103612",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "576527",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4210856-greenlight-capitals-david-einhorn-q3-2018-letter"
            }
        },
        {
            "id": "4204018",
            "type": "article",
            "attributes": {
                "publishOn": "2018-09-04T17:03:53-04:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan Grinding Towards Greatness",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "19358",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4204018-mylan-grinding-towards-greatness"
            }
        },
        {
            "id": "4181508",
            "type": "article",
            "attributes": {
                "publishOn": "2018-06-13T17:32:45-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "With Mylan's Neulasta Biosimilar Approval, Focus Moves To Advair And Restasis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "78545",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "16333",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4181508-mylans-neulasta-biosimilar-approval-focus-moves-to-advair-and-restasis"
            }
        },
        {
            "id": "4179135",
            "type": "article",
            "attributes": {
                "publishOn": "2018-06-04T05:02:43-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: A Margin Of Safety Case Study",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95006",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "15940",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4179135-mylan-margin-of-safety-case-study"
            }
        },
        {
            "id": "4179076",
            "type": "article",
            "attributes": {
                "publishOn": "2018-06-03T16:23:53-04:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan And Coherus: How To Play The Upcoming Neulasta Biosimilar Race",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103833",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4179076-mylan-and-coherus-how-to-play-upcoming-neulasta-biosimilar-race"
            }
        },
        {
            "id": "4153140",
            "type": "article",
            "attributes": {
                "publishOn": "2018-03-05T05:53:59-05:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan's Growth Is Dead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4153140-mylans-growth-is-dead"
            }
        },
        {
            "id": "4151277",
            "type": "article",
            "attributes": {
                "publishOn": "2018-02-27T14:52:39-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: Undervalued Pharmaceutical Company With Potential Near-Term Fundamental Catalysts",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68025",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "12648",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4151277-mylan-undervalued-pharmaceutical-company-potential-near-term-fundamental-catalysts"
            }
        },
        {
            "id": "4150519",
            "type": "article",
            "attributes": {
                "publishOn": "2018-02-26T00:09:15-05:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Institutional Investors' Interest In Teva And Mylan Goes Beyond Berkshire",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102639",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4150519-institutional-investors-interest-in-teva-and-mylan-goes-beyond-berkshire"
            }
        },
        {
            "id": "4137020",
            "type": "article",
            "attributes": {
                "publishOn": "2018-01-11T14:51:41-05:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: The Time Is Ripe",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "69905",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "10667",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4137020-mylan-time-is-ripe"
            }
        },
        {
            "id": "4136111",
            "type": "article",
            "attributes": {
                "publishOn": "2018-01-09T04:01:47-05:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: Did The FDA Clear The Runway For Generic Restasis?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4136111-mylan-fda-clear-runway-for-generic-restasis"
            }
        }
    ]
}